Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD
| Status: | Terminated |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 5/11/2018 |
| Start Date: | September 29, 2016 |
| End Date: | March 3, 2017 |
A Phase 2, Open-label, Single-arm, Intra-subject Dose-escalation Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Moderate or Severe Chronic GVHD Inadequately Responding to First or Second Line Therapy
Chronic graft versus host diseasre (GVHD) is a serious reaction that might occur in a person
(the host) who has received cells or organs (graft) from another person because the graft
attacks the host's cells. Currently there are no approved therapies for chronic GVHD in the
USA, and patients with chroninc GVHD are treated with immunosuppressant drugs. T-lymphocytes
(a type of white blood cells) are likely to play a role in the development of chronic GVHD.
Due to the capacity of ponesimod to block the traffic of T-lymphocytes, ponesimod may be a
new therapeutic approach to treat chroninc GVHD.
The main objective of this study is to assess the effectiveness and safety of several doses
of ponesimod in subjects with chronic GVHD who did not respond to standard available
treatments.
(the host) who has received cells or organs (graft) from another person because the graft
attacks the host's cells. Currently there are no approved therapies for chronic GVHD in the
USA, and patients with chroninc GVHD are treated with immunosuppressant drugs. T-lymphocytes
(a type of white blood cells) are likely to play a role in the development of chronic GVHD.
Due to the capacity of ponesimod to block the traffic of T-lymphocytes, ponesimod may be a
new therapeutic approach to treat chroninc GVHD.
The main objective of this study is to assess the effectiveness and safety of several doses
of ponesimod in subjects with chronic GVHD who did not respond to standard available
treatments.
Inclusion Criteria:
- Signed informed consent
- Symptomatic moderate or severe chronic GVHD patients in need of a change of systemic
immunosuppressant (IS) therapy
- Women of child bearing potential must have a negative pregnancy test and use reliable
methods of contraception
Exclusion Criteria:
- Clinically significant medical conditions including active or uncontrolled infections,
new or recurrent malignancy, serious cardiac, pulmonary, or renal disease, and
uncontrolled diabetes.
- Karnofsky Performance Score < 60.
- Immunosuppressant therapies other than allowed background therapy
- Anti-arrhythmic and heart rate lowering drugs.
- Any other circumstances or conditions, which, in the opinion of the investigator, may
affect full participation in the study or compliance with the protocol
We found this trial at
10
sites
Stony Brook University Medical Center Stony Brook Medicine expresses our shared mission of research, clinical...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials